{"id":"adalimumab-40-mg","safety":{"commonSideEffects":[{"rate":"12-15%","effect":"Injection site reactions"},{"rate":"7-10%","effect":"Upper respiratory tract infections"},{"rate":"5-8%","effect":"Headache"},{"rate":"1-3%","effect":"Serious infections (including tuberculosis)"},{"rate":"low but increased relative to placebo","effect":"Malignancy risk"}]},"_chembl":{"chemblId":"CHEMBL133572","moleculeType":"Small molecule","molecularWeight":"681.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking TNF-α, adalimumab reduces inflammatory signaling and immune activation in conditions driven by excessive TNF-α production. This leads to decreased inflammation, reduced immune cell infiltration, and suppression of downstream inflammatory mediators. It is used across multiple autoimmune and inflammatory conditions where TNF-α plays a central pathogenic role.","oneSentence":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:31.374Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Psoriasis"},{"name":"Juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT06654882","phase":"PHASE3","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-09","conditions":"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)","enrollment":400},{"nctId":"NCT04527380","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2021-04-13","conditions":"Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis","enrollment":101},{"nctId":"NCT06045754","phase":"PHASE4","title":"A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-04-18","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT04870203","phase":"PHASE3","title":"Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2021-07-15","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT07061574","phase":"PHASE1, PHASE2","title":"A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-03-30","conditions":"Type 1 Diabetes, New Onset","enrollment":120},{"nctId":"NCT06996652","phase":"PHASE2","title":"An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-04","conditions":"REM Sleep Behavior Disorder","enrollment":108},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT07423533","phase":"PHASE2","title":"Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2026-02","conditions":"Rheumatoid Arthritis","enrollment":450},{"nctId":"NCT06016517","phase":"","title":"Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Tufts Medical Center","startDate":"2026-03-15","conditions":"Arthritis, Rheumatoid","enrollment":18},{"nctId":"NCT06440629","phase":"PHASE4","title":"Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)","status":"RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2024-08-20","conditions":"Rheumatoid Arthritis","enrollment":350},{"nctId":"NCT06941376","phase":"PHASE2","title":"An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-08-01","conditions":"Relapsing Polychondritis","enrollment":20},{"nctId":"NCT05305066","phase":"NA","title":"Stand UP to Rheumatoid Arthritis (SUPRA)","status":"RECRUITING","sponsor":"Marie Hudson, MD","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT03153319","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2017-06-05","conditions":"Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI","enrollment":14},{"nctId":"NCT07147257","phase":"PHASE1","title":"A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions","status":"COMPLETED","sponsor":"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.","startDate":"2025-02-12","conditions":"Healthy Participants","enrollment":238},{"nctId":"NCT01382160","phase":"PHASE4","title":"Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2011-01","conditions":"Rheumatoid Arthritis","enrollment":69},{"nctId":"NCT05590455","phase":"PHASE2","title":"Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-04-11","conditions":"Tuberculous Meningitis, HIV I Infection","enrollment":130},{"nctId":"NCT06180382","phase":"PHASE4","title":"Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2024-10-31","conditions":"Crohn's Disease","enrollment":220},{"nctId":"NCT03651518","phase":"PHASE2","title":"Personalized Therapies in Inflammatory Complex Disease","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-10-20","conditions":"Inflammatory Disease, Autoimmune Diseases","enrollment":32},{"nctId":"NCT07181694","phase":"PHASE1","title":"A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects","status":"RECRUITING","sponsor":"Biocad","startDate":"2025-03-12","conditions":"Healthy Adult Male","enrollment":444},{"nctId":"NCT03104400","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-04-27","conditions":"Psoriatic Arthritis","enrollment":1705},{"nctId":"NCT02929251","phase":"PHASE2","title":"Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-29","conditions":"Uveitis, Biotherapy","enrollment":112},{"nctId":"NCT01385826","phase":"PHASE2, PHASE3","title":"Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-06-29","conditions":"Uveitis, Juvenile Arthritis","enrollment":34},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT06729463","phase":"NA","title":"IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients","status":"COMPLETED","sponsor":"South Valley University","startDate":"2024-12-01","conditions":"Psoriasis, Psoriatic Arthritis","enrollment":50},{"nctId":"NCT03316781","phase":"PHASE3","title":"Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2017-10-27","conditions":"Plaque Psoriasis","enrollment":262},{"nctId":"NCT04985435","phase":"PHASE4","title":"Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)","status":"RECRUITING","sponsor":"R.Bos","startDate":"2021-05-12","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT02629159","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2015-12-01","conditions":"Rheumatoid Arthritis","enrollment":1629},{"nctId":"NCT05928039","phase":"PHASE4","title":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-10-25","conditions":"Crohn Disease","enrollment":297},{"nctId":"NCT05108259","phase":"PHASE1","title":"To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects","status":"RECRUITING","sponsor":"Prestige Biopharma Limited","startDate":"2022-03-30","conditions":"Healthy Volunteers","enrollment":324},{"nctId":"NCT03261102","phase":"NA","title":"TDM Guided Early Optimization of ADAL in Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"waqqas.afif","startDate":"2017-01-17","conditions":"Crohn Disease, Drug Monitoring, Inflammatory Bowel Diseases","enrollment":200},{"nctId":"NCT06310837","phase":"NA","title":"Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2024-03-27","conditions":"Uveitis","enrollment":128},{"nctId":"NCT03828019","phase":"PHASE3","title":"Adalimumab vs. Conventional Immunosuppression for Uveitis Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2019-09-16","conditions":"Uveitis","enrollment":227},{"nctId":"NCT03464136","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2018-03-29","conditions":"Crohn Disease","enrollment":386},{"nctId":"NCT03906136","phase":"PHASE3","title":"AScalate: Treat-to-target in Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-04","conditions":"Axial Spondyloarthritis","enrollment":304},{"nctId":"NCT04088409","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2019-10-16","conditions":"Uveitis","enrollment":30},{"nctId":"NCT05313620","phase":"PHASE4","title":"Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events","status":"RECRUITING","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2022-04-01","conditions":"Ulcerative Colitis, Thromboembolism","enrollment":30},{"nctId":"NCT03885713","phase":"PHASE4","title":"Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2019-09-10","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","enrollment":180},{"nctId":"NCT03505008","phase":"PHASE4","title":"Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan","status":"COMPLETED","sponsor":"Keio University","startDate":"2018-04-18","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT06849908","phase":"PHASE2","title":"Baricitinib in the Treatment of Intestinal Behçet's Syndrome","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-11-08","conditions":"Behcet Syndrome, Intestinal Type","enrollment":56},{"nctId":"NCT02706704","phase":"PHASE2","title":"Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis","status":"RECRUITING","sponsor":"American University of Beirut Medical Center","startDate":"2016-02","conditions":"Uveitis, Non-Infectious Uveitis","enrollment":32},{"nctId":"NCT04909801","phase":"PHASE3","title":"A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-09-15","conditions":"Rheumatoid Arthritis","enrollment":338},{"nctId":"NCT05180526","phase":"PHASE4","title":"Assessment of Safety , Clinical Efficacy with QLETLI in Non-infectious Uveitis (UV)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bio-Thera Solutions","startDate":"2021-12-27","conditions":"Uveitis","enrollment":60},{"nctId":"NCT05169593","phase":"PHASE4","title":"Prevention of Postoperative Endoscopic Recurrence with Endoscopy-driven Versus Systematic Biological Therapy","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2022-09-08","conditions":"Crohn Disease","enrollment":292},{"nctId":"NCT06062875","phase":"PHASE2","title":"Effects of TNF Blockade on Human BPH/LUTS","status":"RECRUITING","sponsor":"Endeavor Health","startDate":"2024-01-24","conditions":"Benign Prostatic Hyperplasia (BPH)","enrollment":70},{"nctId":"NCT05637515","phase":"PHASE3","title":"Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity","status":"COMPLETED","sponsor":"Biocon Biologics Inc.","startDate":"2022-11-21","conditions":"Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis","enrollment":374},{"nctId":"NCT05495568","phase":"PHASE3","title":"To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2022-11-07","conditions":"Moderate to Severe Chronic Plaque Psoriasis","enrollment":367},{"nctId":"NCT06527534","phase":"PHASE4","title":"Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)","status":"RECRUITING","sponsor":"Universita di Verona","startDate":"2024-07-15","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT02450513","phase":"","title":"Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2012-03","conditions":"Crohn's Disease","enrollment":30},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT05590416","phase":"","title":"A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease","status":"RECRUITING","sponsor":"Tianjin Medical University","startDate":"2021-06-01","conditions":"Vogt-Koyanagi-Harada Disease, Adalimumab","enrollment":15},{"nctId":"NCT06291948","phase":"PHASE1","title":"A Clinical Study With Adalimumab Biosimilar","status":"COMPLETED","sponsor":"Laboratorios Richmond S.A.C.I.F.","startDate":"2022-08-01","conditions":"Pharmacokinetics, Safety Issues","enrollment":150},{"nctId":"NCT05115903","phase":"PHASE4","title":"Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-12-01","conditions":"Axial Spondyloarthritis","enrollment":15},{"nctId":"NCT02660580","phase":"PHASE3","title":"MSB11022 in Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2016-02-16","conditions":"Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis","enrollment":443},{"nctId":"NCT06005532","phase":"PHASE3","title":"Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®","status":"UNKNOWN","sponsor":"Mabscale, LLC","startDate":"2023-10-02","conditions":"Plaque Psoriasis","enrollment":494},{"nctId":"NCT05527444","phase":"PHASE4","title":"The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-03-15","conditions":"Ankylosing Spondylitis","enrollment":100},{"nctId":"NCT04988308","phase":"PHASE2","title":"A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-12","conditions":"Hidradenitis Suppurativa","enrollment":151},{"nctId":"NCT04798755","phase":"PHASE3","title":"Efficacy, Safety and Costs of Methotrexate, Adalimumab, or Their Combination in Non-infectious Non-anterior Uveitis","status":"UNKNOWN","sponsor":"Hospital San Carlos, Madrid","startDate":"2022-01-12","conditions":"Uveitis","enrollment":192},{"nctId":"NCT02760407","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2016-06-06","conditions":"Rheumatoid Arthritis","enrollment":1648},{"nctId":"NCT04261010","phase":"NA","title":"TNF and IL23 Blocking Agents Gene Expression Ratios in the Psoriatic Arthritis Synovium_(TIGERS) Study","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2020-01-14","conditions":"Psoriatic Arthritis","enrollment":36},{"nctId":"NCT03259074","phase":"PHASE3","title":"Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-11-30","conditions":"Ankylosing Spondylitis","enrollment":859},{"nctId":"NCT05957120","phase":"","title":"Subclinical Impairment of Cardiovascular System in Patients With Psoriasis","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2022-01-03","conditions":"Psoriasis, Inflammation, Endothelial Dysfunction","enrollment":100},{"nctId":"NCT02764762","phase":"PHASE4","title":"Triple Combination Therapy in High Risk Crohn's Disease (CD)","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-18","conditions":"Crohn Disease","enrollment":55},{"nctId":"NCT05909852","phase":"PHASE1","title":"A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-07-23","conditions":"Adalimumab","enrollment":372},{"nctId":"NCT05871086","phase":"PHASE2, PHASE3","title":"Coenzyme Q10 in Juvenile Idiopathic Arthritis Patients","status":"UNKNOWN","sponsor":"Nourhan Elsherif","startDate":"2023-05-01","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT03306446","phase":"PHASE4","title":"Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab","status":"UNKNOWN","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2015-03-17","conditions":"CD","enrollment":203},{"nctId":"NCT05874505","phase":"PHASE2","title":"\"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease\"","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07","conditions":"Behcet's Uveitis","enrollment":60},{"nctId":"NCT05510063","phase":"PHASE4","title":"Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2022-08-04","conditions":"Plaque Psoriasis","enrollment":371},{"nctId":"NCT03619876","phase":"PHASE4","title":"Effects of Abatacept on Myocarditis in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Columbia University","startDate":"2019-07-10","conditions":"Rheumatoid Arthritis, Myocardial Inflammation","enrollment":11},{"nctId":"NCT02994836","phase":"PHASE4","title":"GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2017-04-21","conditions":"Crohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis","enrollment":139},{"nctId":"NCT05720221","phase":"","title":"Biologics in Management of Inflammatory Bowel Disease in Egyptian Patients","status":"COMPLETED","sponsor":"Helwan University","startDate":"2021-07-15","conditions":"IBD","enrollment":100},{"nctId":"NCT05683054","phase":"PHASE4","title":"A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are Overtreated","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2020-08-11","conditions":"Psoriasis","enrollment":19},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT02374021","phase":"PHASE4","title":"Treatments Against RA and Effect on FDG-PET/CT","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-07","conditions":"Arthritis, Rheumatoid","enrollment":159},{"nctId":"NCT03172377","phase":"PHASE4","title":"Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2017-05-03","conditions":"Crohn Disease in Remission, Crohn Disease","enrollment":174},{"nctId":"NCT05502731","phase":"PHASE4","title":"Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2022-10","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT05172817","phase":"PHASE2, PHASE3","title":"Study to Compare PK & Safety of Advixa With Humira in Healthy, Adult Subject Followed by Efficacy & Safety Study in RA Patients","status":"UNKNOWN","sponsor":"Institute for Developing Science and Health Initiatives, Bangladesh","startDate":"2021-06-02","conditions":"Pharmacokinetics, Safety, Efficacy","enrollment":200},{"nctId":"NCT05427942","phase":"","title":"Yuflyma® (Adalimumab), Patient Experience After Switching","status":"UNKNOWN","sponsor":"Celltrion HealthCare France","startDate":"2022-06-03","conditions":"Rheumatoid Arthritis, Ankylosing Spondylarthritis, Axial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis","enrollment":300},{"nctId":"NCT04115748","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2019-12-03","conditions":"Psoriatic Arthritis","enrollment":67},{"nctId":"NCT03357939","phase":"PHASE1","title":"Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2017-01-12","conditions":"Immune System Disorder","enrollment":220},{"nctId":"NCT03849313","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-03-20","conditions":"Healthy Volunteers","enrollment":390},{"nctId":"NCT04453137","phase":"PHASE3","title":"Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2020-06-30","conditions":"Plaque Psoriasis","enrollment":567},{"nctId":"NCT02332590","phase":"PHASE3","title":"Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01-28","conditions":"Rheumatoid Arthritis","enrollment":369},{"nctId":"NCT02714322","phase":"PHASE3","title":"MYL-1401A Efficacy and Safety Comparability Study to Humira®","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-06","conditions":"Psoriasis, Arthritis, Psoriatic","enrollment":294},{"nctId":"NCT02472912","phase":"PHASE1","title":"Adalimumab PK Bioequivalence Study to EU and US Sourced Humira","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2014-12","conditions":"Healthy Volunteers","enrollment":270},{"nctId":"NCT04705844","phase":"PHASE3","title":"Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)","status":"WITHDRAWN","sponsor":"Alachua Government Services, Inc.","startDate":"2021-09","conditions":"Mild to Moderate COVID-19","enrollment":""},{"nctId":"NCT00730717","phase":"PHASE2","title":"Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum","status":"WITHDRAWN","sponsor":"Wright State University","startDate":"2009-05","conditions":"Pyoderma Gangrenosum","enrollment":""},{"nctId":"NCT00731757","phase":"PHASE2","title":"Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis","status":"WITHDRAWN","sponsor":"Wright State University","startDate":"2009-05","conditions":"Sarcoidosis, Cutaneous Sarcoidosis","enrollment":""},{"nctId":"NCT01971970","phase":"","title":"Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2013-10","conditions":"Inflammatory Bowel Diseases","enrollment":45},{"nctId":"NCT04588818","phase":"PHASE2","title":"Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-02-01","conditions":"Uveitis","enrollment":30},{"nctId":"NCT05153200","phase":"PHASE4","title":"Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2022-01","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT01373151","phase":"PHASE2","title":"Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2011-06","conditions":"Rheumatoid Arthritis","enrollment":418},{"nctId":"NCT03970824","phase":"PHASE1","title":"To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-05-31","conditions":"Healthy","enrollment":312},{"nctId":"NCT02395055","phase":"PHASE1","title":"Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2015-06","conditions":"Healthy","enrollment":94},{"nctId":"NCT02471118","phase":"PHASE2","title":"Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA)","status":"COMPLETED","sponsor":"CARE ARTHRITIS LTD.","startDate":"2015-03","conditions":"Osteoarthritis, Knee","enrollment":62},{"nctId":"NCT02256462","phase":"PHASE4","title":"Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial","status":"COMPLETED","sponsor":"Schneider Children's Medical Center, Israel","startDate":"2015-05-01","conditions":"Crohn's Disease","enrollment":82},{"nctId":"NCT00837434","phase":"PHASE4","title":"Anti-TNF Agents for the Treatment of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":63},{"nctId":"NCT02762955","phase":"PHASE3","title":"Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Biocad","startDate":"2016-12","conditions":"Psoriasis","enrollment":344},{"nctId":"NCT02092467","phase":"PHASE4","title":"Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03-14","conditions":"Arthritis, Rheumatoid","enrollment":4372},{"nctId":"NCT03607903","phase":"PHASE1, PHASE2","title":"Adalimumab Microneedles in Healthy Volunteers","status":"COMPLETED","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2018-07-11","conditions":"Pain, Injection Site","enrollment":24}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"HEADACHE"},{"count":1,"reaction":"ABDOMINAL WALL ABSCESS"},{"count":1,"reaction":"ABSCESS DRAINAGE"},{"count":1,"reaction":"ADRENAL INSUFFICIENCY"},{"count":1,"reaction":"AORTITIS"},{"count":1,"reaction":"B-CELL LYMPHOMA"},{"count":1,"reaction":"BLOOD PRESSURE SYSTOLIC INCREASED"},{"count":1,"reaction":"BRONCHITIS"},{"count":1,"reaction":"CSF PROTEIN INCREASED"},{"count":1,"reaction":"DIFFUSE ALVEOLAR DAMAGE"}],"_approvalHistory":[],"publicationCount":380,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Humira","HUMIRA®"],"phase":"phase_3","status":"active","brandName":"Adalimumab (40 mg)","genericName":"Adalimumab (40 mg)","companyName":"Janssen Scientific Affairs, LLC","companyId":"janssen-scientific-affairs-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}